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specificity that phosphorylates and activates the third kinase (MAPK), which is the main pathway effector and usually has multiple substrates (1). The biological reason for this design is unclear. Theoretical considerations suggest that it enables high signaling rates and amplification, while providing stable off states (2) . Negative feedback loops (NFLs) are predicted to add rich dynamic properties to signaling pathways, such as oscillations and switch-like responses (3) . In metabolic pathways, NFLs stabilize end-product concentrations with respect to changes in consumption rates or substrate input supplies (4) .
Combining experimental and mathematical analysis, we show that the integration of a kinase cascade amplifier with NFLs generates emergent system-level properties that resemble the negative feedback amplifier (NFA) known from engineering, and that these NFA-like properties affect drug sensitivity and adaptation to perturbations of cells. We analyzed the extracellular signal-regulated kinase (ERK) MAPK pathway, which regulates fundamental cellular processes including proliferation, survival, transformation, differentiation, and motility (5, 6) . ERK signaling is initiated by cell surface receptors that activate Ras by recruiting guanine nucleotide exchange factors, such as SOS, which load Ras with GTP (5, 7, 8) . RasGTP binds mitogen-activated protein kinase kinase kinases (MAPKKKs) of the Raf family with high affinity, translocating them from the cytosol to the cell membrane where they become activated. Active Raf phosphorylates and activates mitogen-activated or extracellular signal-regulated protein kinase kinase (MEK), which in turn phosphorylates and activates ERK.
Results
The NFA design and experimental approaches to examine NFA-like properties of the
Raf-MEK-ERK pathway
In engineering, the NFA design ( Fig. 1A) is widely used for controlling dynamic processes to reduce the effects of input noise, buffer perturbations in the amplifier, and smoothen output responses (9, 10) . In a Raf-MEK-ERK biological circuit, the input signal coming from receptors proceeds through activated RasGTP to the amplifier, represented by the Raf-MEK-ERK module (Fig. 1B) . The ratio of protein abundances of Raf-1, MEK, and ERK is approximately 1:3:6 in COS cells and 1:0.7:9 in NIH 3T3 fibroblasts ( Fig. S1 ), thus permitting signal amplification. A direct NFL from ERK to SOS, involving its phosphorylation and inhibition (11), inhibits Ras activation; and another NFL involves Raf-1 phosphorylation and inhibition (12) by activated ERK. A key property of a NFA is to convey robustness against perturbations to the amplifier (Fig. 1C ), while still linearly transmitting input signals ( Fig. 1D ). To explore the NFA properties of the ERK pathway, we modeled it as either a simple amplifier ("Feedback Broken") or as a NFA ("Feedback Intact") using ordinary differential equations (Supplementary Materials, sections 1. ) had no effect on BXB-ER activity, but prolonged the activity of Raf-1. Cells expressing Raf6A had slightly increased basal kinase activity, which was stimulated by EGF, but in contrast to Raf-1, was sustained even in the absence of U0126 (Fig. 1F ). These results showed that the negative feedback limits the duration of Raf-1 activation, and that our experimental tools are suitable to interrogate the NFA design.
Conversion of switch-like ERK activation into a graded response by the NFA like design
In the ERK pathway, amplifier distortions arise naturally because MEK phosphorylates each of the two sites required for full ERK activity separately rather than processively during one binding event (16, 17) . As a result, the single phosphorylated, low activity form of ERK is generated during the initial activation phase. When enough single phosphorylated ERK has accumulated, every new phosphorylation event produces double phosphorylated, fully activated ERK, which is apparent as a steep nonlinear increase in ERK activation kinetics (18) . This hypersensitive mode of activation changes the internal gain of the amplifier in a nonlinear fashion resulting in a switch-like response, which is predicted by our mathematical model ( Fig. 2A) , and was observed experimentally in Xenopus oocytes (19) . According to our mathematical NFA model simulations ( Fig. 2A ), the negative feedback should convert the switch-like, hypersensitive response into a more graded response by reducing the sensitivity of the reactions in the amplifier module to perturbations ( Fig. 2A ). To test this prediction theoretically, we performed sensitivity analysis of the mathematical model ( Fig. 2B , Supplementary Materials, section 1.5).
Sensitivity coefficients provide a quantitative measurement of how changes in individual
reactions affect the output, here measured as the abundance of doubly phosphorylated ERK (ppERK). Elimination of the negative feedback increased the sensitivity coefficients of most reactions in the amplifier module, especially the reactions that activate and deactivate MEK. This increase in the sensitivity coefficients in the amplifier module is explained by the mathematical model because the strength of the negative feedback is directly coupled to the gain of the amplifier, which corrects variations in the parameters in the amplifier module. Thus, the biological NFA allowed signal amplification but made the system resilient to amplifier perturbations.
The theoretical analysis of the NFA model predicted that ERK activation should be switchlike in absence of negative feedback, but graded when it is present. To test this prediction experimentally, we analyzed ERK activation by flow cytometry, which measures ERK activity in individual cells of a population (Fig. 2C ). In the Feedback Intact system, ERK activation increased in a graded manner proportional to the stimulation. However, in the Feedback Broken system, the response became switch-like, in which individual cells either responded or not, and the number of responding cells increased in proportion to the stimulation. Thus, the presence or absence of the NFLs can determine whether the response of the kinase module is graded or switch-like ( Fig. 2D ). This may explain divergent results about the activation kinetics of the ERK cascade in different biological systems. Although it has switch-like properties in Xenopus oocytes (19) , subsequent studies in mammalian cells found that it responded in a graded fashion (20, 21) . In Xenopus oocytes the main mitotic activator of the ERK module is not Raf-1 but c-Mos (22) . c-Mos lacks the Rasbinding domain and the ERK phosphorylation sites, and hence is not subjected to negative feedback regulation by ERK resulting in switch-like ERK activation dynamics. However, in mammalian cells in which Raf-1 activates MEK, growth factor stimulation permits the NFA properties to buffer the intrinsic hypersensitivity of the amplifier and generate a graded response.
The NFA-like design and drug sensitivity
Another salient prediction of the NFA model is that ERK activation should be resilient to disturbances of the amplifier (Fig. 1C ). To test this prediction, we used the MEK-selective inhibitor U0126 (14, 15) . Computational simulations of U0126 dose-response curves predicted high sensitivity of ERK activation to MEK inhibition in the absence of NFLs (Feedback Broken), and resistance to MEK inhibition in the presence of the NFA (Feedback Intact) ( Fig. 3A) . To test this prediction, we treated cells having either the negative feedback intact or broken with varying amounts of the MEK-selective inhibitor U0126, stimulated them with either EGF (Feedback Intact) or 4-HT (Feedback Broken) and
then measured ERK activation (14, 15) . As predicted by our model, in the Feedback Broken system, ERK activation was thoroughly inhibited by low concentrations of U0126, whereas in the Feedback Intact system ERK activity persisted even in the presence of high U0126 concentrations ( Fig. 3B ). With the negative feedback intact, increasing U0126 concentrations weakened the negative feedback and allowed the amplifier gain to rise, thus causing increased resistance to U0126. As inhibitor concentrations were increased further, resistance persisted until U0126 concentrations were high enough to achieve complete inhibition.
We also observed enhanced sensitivity to low U0126 concentrations in the Feedback Intact system. This effect can be explained by three mechanisms, which can operate separately or jointly depending on conditions and inhibitor properties. First, low inhibitor concentrations are inherently associated with linear inhibition kinetics that precede the flattening out of the inhibition curve when rising inhibitor concentrations push the system towards saturation.
Linear inhibition ranges are generally larger for tightly bound inhibitors, such as U0126 (15) . Second, the allosteric mode of inhibition by U0126 fixes MEK in a nonfunctional conformation and prevents MEK from interacting with ERK (23). Thus, U0126 not only prevents MEK from binding to ERK, but also disrupts MEK-ERK complexes (reactions 27-35 in table S1), making inhibition more efficient. Third, if the concentration of ppERK is larger than the abundance of the upstream activator Raf-1 ( fig. S1 ), the negative feedback becomes saturated. In this last scenario, a large reduction of ppERK would be required before Raf-1 inhibition eased and the feedback weakened to allow the increase of input to compensate for the inhibition. The sensitivities to MEK inhibition that we observed in the computational simulations were obtained using the parameter values from the model by Schoeberl et al. (24) . To test whether variations in the concentrations of Raf-1, MEK, and ERK affected the model, we concentrations of the MEK inhibitor. These results also showed that the biological circuit is more complex than the classic electronic circuit. One main difference is the temporal element of feedback regulation, which is immediate in the classic electronic NFA, but can be delayed or operating on different parallel timescales in the biological design. Because the effects of U0126 included parallel effects that can occur on different timescales, we tested a situation where U0126 was applied at the peak of ERK activation ( fig. S6 ). In the Feedback Broken system, U0126 caused full ERK inhibition, whereas the Feedback Intact system exhibited dampened inhibition, resulting in a partial recovery to a new steady state of ERK activity above the basal activity. These results suggest that the NFA-like design of biological systems can dynamically buffer amplifier perturbations over time.
The model also predicts that inhibition of components that are not part of the biological NFA should be more effective than inhibition of components within the NFA (Fig. 3A .
This prediction was corroborated by comparing the effects of 4557W, an EGF receptor (EGFR) inhibitor, with that of U0126 (Fig. 3B ). Inhibition of EGFR produced an almost linear dose-response relationship both in the model and in the experimental system. This suggests that proteins embedded in NFA-like topologies make suboptimal drug targets, because the effects of their inhibition are dampened.
We also tested the effects of the biological NFA with the "Feedback Partially Broken" system based on the Raf6A mutant (12) to partially break the negative feedback.
Unfortunately, due to cytotoxic effects, we could not obtain cells expressing Raf6A alone in the absence of endogenous Raf-1. Therefore, we used COS1 cells stably expressing similar amounts of Raf-1 or Raf6A (fig. S4 ). These cells were stimulated with EGF and treated with increasing doses of U0126. In response to EGF stimulation, cells expressing
Raf6A were more sensitive to MEK inhibition than were cells expressing Raf-1 (Fig. 4A, upper left). To examine the specificity of the NFA-like effect we tested different growth factors, in particular platelet-derived growth factor (PDGF) and insulin-like growth factor (IGF1), factors for which COS1 cells have receptors. PDGF-activated ERK showed a NFAlike response that was similar but smaller than the response to EGF, with cells expressing
Raf6A showing decreased resistance to U0126 (Fig. 4A, upper fig. S7 ), which weakens the influence of the NFA (Fig. 1A) . Curiously, stimulation of ERK by IGF1 did not exhibit the NFA-like property that partial loss of negative feedback made the MEK inhibitor more effective in reducing ERK activation (Fig. 4A, lower right) . We found that IGF1 selectively activated Comment [NG8]: Please verify that you mean figure 3B , there is no figure 3D . Fig. 3B is correct B-Raf and not Raf-1 (Fig. 4B) Raf-1 as the main activator of the ERK pathway in melanoma (28) highlight the possibility that this switch could be accompanied by increased resistance to MEK inhibitors due to the acquisition of NFA-like properties. Our results predict that breaking the NFA is essential to ensure sensitivity to MEK inhibitors.
Therefore, we used our model to suggest scenarios for disabling the biological NFA. One possibility is to inhibit targets outside of the biological NFA (Figs. 3A, B, Fig. 4A ). An alternative prediction of the mathematical NFA model was that Raf-1 inhibition should sensitize the pathway to MEK inhibition by weakening the NFA effect (Fig. 5A) 
Comment [NG10]:
Correct that you mean the PDGF receptor inhibitor graph in figure 4A ? There is no figure 4C . Correct the sensitivity to MEK inhibition in the Feedback Intact system (Fig. 5B, left) . The cooperative effects of Raf and MEK inhibition were absent in the Feedback Broken system ( Fig. 5B, right) .
Discussion
These results suggest that the ERK pathway has intrinsic design features like that of a NFA. targets (29, 30) . However, it has proven difficult to predict which components should be targeted, and the cornucopia of potential drug targets is contrasted by a paucity of objective criteria for how to choose amongst them. Our results suggest that inhibition of a pathway by inhibiting targets embedded in a NFA-like topology is more difficult to achieve than the effect of inhibiting targets outside of the feedback loop, which provides a simple drug target selection guideline that is deductible from the network structure. The NFA-like properties also suggest that drugs that inhibit targets within the NFA circuit may be more effective if the negative feedback loops are also blocked or inhibited, thus providing insight into potentially effective combination therapies. On a more speculative note, the results also suggest that biological evolution and engineered systems may converge to similar solutions when designing robustness.
Materials and Methods

Reagents and plasmids
Growth factors, drugs and pharmacological inhibitors were from commercial sources and used according to suppliers' recommendations or as indicated. Antibodies that recognize phosphorylated ERK1 and 2 (ERK1/2) and antibodies that recognize ERK1/2 for immunoblotting were purchased from Cell Signaling. Antibodies that recognize C-Raf-1 and antibodies that recognize hemagglutinin (HA) for immunoprecipitation were purchased BD Bioscience and Roche, respectively.
Cell culture
Stable BXB-ER NIH/3T3 cells were described (31) , and COS1 cell lines stably expressing BXB-ER were generated similarly.
Dose-response curves
BXB-ER COS-1, NIH 3T3 wt-Raf-1, or NIH 3T3 6A-Raf-1 cells were starved in serumfree medium overnight. The cells were pre-incubated with the indicated amounts of inhibitors U0126, 4557W, or D-64406 for 1 hour and subsequently stimulated with 50 ng/ml growth factors or 0.1 μM 4-hydroxy-tamoxifen (4HT). The stimulation was stopped by washing the cells with ice-cold PBS and immediate freezing at -80°C.
Immunoprecipitation, immunoblotting, and immunocomplex kinase assays
Cells were treated with growth factors with or without inhibitors as indicated and lysed in 25 mM HEPES pH 7.4, 50 mM NaCl, 5 mM EDTA, 1 % Triton X-100 supplemented with protease inhibitor cocktail (Roche) and phosphatase inhibitors (2mM NaF, 0.2mM NaP 2 O 5 , 0.5mM sodium orthovanadate, 10mM β-glycerophosphate). Immunoprecipitations, Western blotting, and kinase assays were performed as described (25) . Western blots were developed and scanned using Licor technology (http://www.licor.com/bio/index.jsp), which is a quantitative technique for staining Western blots based on infrared imaging.
Fluorescence-activated cell sorting
Fluorescence-activated cell sorting was performed as described (32) . Cells were serum starved for 2 hours, treated as indicated, and stained with Alexa 488-conjugated antibodies against phosphorylated ERK (Invitrogen). Fluorescence profiles were measured on a FACSCalibur (BD Biosciences) using CellQuest Pro software. Distribution profiles were produced using FlowJo software (7.2.2). Data fitting was performed using Microsoft Excel and GraphPad Prism.
Models and Modelling
The mathematical models were based on mass action models using ordinary differential equations of an adapted version of the core ERK pathway described in (24) . Two computational models, "Feedback Intact" and "Feedback Broken," were developed to investigate the NFA characteristics of the ERK pathway. The NFA-like model is the 
